+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Community-Acquired Bacterial Pneumonia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767776
  • Report
  • April 2019
  • Region: Global
  • 67 pages
  • VPA Research

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Cempra Inc
  • GlaxoSmithKline Plc
  • Nabriva Therapeutics AG
  • Novartis AG
The global clinical trial report- “2019 Community-Acquired Bacterial Pneumonia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Community-Acquired Bacterial Pneumonia. It presents in-depth analysis of Community-Acquired Bacterial Pneumonia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Community-Acquired Bacterial Pneumonia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Community-Acquired Bacterial Pneumonia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Community-Acquired Bacterial Pneumonia

The research work is prepared through extensive and continuous research on Community-Acquired Bacterial Pneumonia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Community-Acquired Bacterial Pneumonia patients are identified
  • The report includes panorama of Community-Acquired Bacterial Pneumonia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Community-Acquired Bacterial Pneumonia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Cempra Inc
  • GlaxoSmithKline Plc
  • Nabriva Therapeutics AG
  • Novartis AG
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Community-Acquired Bacterial Pneumonia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Community-Acquired Bacterial Pneumonia Clinical Trials by Region
2.2.2 Average Enrollment of Community-Acquired Bacterial Pneumonia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Community-Acquired Bacterial Pneumonia Treatment, 2019

3. Region wise Community-Acquired Bacterial Pneumonia Clinical Trials
3.1 Asia Pacific Community-Acquired Bacterial Pneumonia Clinical Trials by Country
3.2 Europe Community-Acquired Bacterial Pneumonia Clinical Trials by Country
3.3 North America Community-Acquired Bacterial Pneumonia Clinical Trials by Country
3.4 Middle East and Africa Community-Acquired Bacterial Pneumonia Clinical Trials by Country
3.5 South and Central America Community-Acquired Bacterial Pneumonia Clinical Trials by Country

4. Community-Acquired Bacterial Pneumonia Clinical Trial Trends
4.1 Start Year wise Community-Acquired Bacterial Pneumonia Clinical Trials
4.2 Phase wise Community-Acquired Bacterial Pneumonia Clinical Trials
4.3 Trial Status wise Community-Acquired Bacterial Pneumonia Clinical Trials
4.4 Trial Type wise Community-Acquired Bacterial Pneumonia Clinical Trials

5. Community-Acquired Bacterial Pneumonia Average Enrollment Trends
5.1 Average Enrollment in Community-Acquired Bacterial Pneumonia Trials by Year
5.2 Average Enrollment in Community-Acquired Bacterial Pneumonia Trials by Phase
5.3 Average Enrollment in Community-Acquired Bacterial Pneumonia Trials by Status
5.4 Average Enrollment in Community-Acquired Bacterial Pneumonia Trials by Type of Trial

6. Companies Participating in Community-Acquired Bacterial Pneumonia Clinical Trials
6.1 Community-Acquired Bacterial Pneumonia Trials by Sponsor Type
6.2 Community-Acquired Bacterial Pneumonia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Community-Acquired Bacterial Pneumonia Trials- Phase 1
7.2 Community-Acquired Bacterial Pneumonia Trials- Phase 2
7.3 Community-Acquired Bacterial Pneumonia Trials- Phase 3
7.4 Community-Acquired Bacterial Pneumonia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Community-Acquired Bacterial Pneumonia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Figure 7: North America - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Figure 9: Community-Acquired Bacterial Pneumonia Clinical Trials by Phase
Figure 10: Community-Acquired Bacterial Pneumonia Clinical Trials by Trial Status
Figure 11: Community-Acquired Bacterial Pneumonia Clinical Trials by Type
Figure 12: Community-Acquired Bacterial Pneumonia Clinical Trials by Sponsor Type
Figure 13: Community-Acquired Bacterial Pneumonia Clinical Trials by Leading Sponsors
Figure 14: Community-Acquired Bacterial Pneumonia Average Enrollment by Phase
Figure 15: Community-Acquired Bacterial Pneumonia Average Enrollment by Trial Status
Figure 16: Community-Acquired Bacterial Pneumonia Average Enrollment by Type
Figure 17: Community-Acquired Bacterial Pneumonia- Average Enrolment by Type of Sponsors
Figure 18: Community-Acquired Bacterial Pneumonia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Community-Acquired Bacterial Pneumonia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Table 5: Europe - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Table 7: North America - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Community-Acquired Bacterial Pneumonia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Community-Acquired Bacterial Pneumonia Average Enrollment by Phase
Table 15: Community-Acquired Bacterial Pneumonia Average Enrollment by Trial Status
Table 16: Community-Acquired Bacterial Pneumonia Average Enrollment by Type
Table 17: Community-Acquired Bacterial Pneumonia- Average Enrolment by Type of Sponsors
Table 18: Community-Acquired Bacterial Pneumonia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Allergan Plc
  • AstraZeneca Plc
  • Cempra Inc
  • GlaxoSmithKline Plc
  • Nabriva Therapeutics AG
  • Novartis AG
  • Pfizer Inc
  • Pharmaceutical Product Development LLC
  • SFBC Anapharm
  • Torrent Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll